Literature DB >> 6537909

Cell adhesion and experimental metastasis: a study using the B16 malignant melanoma model system.

P Elvin, C W Evans.   

Abstract

The adhesive properties of B16F1 and B16F10 cells have been studied following their rates of attachment to various substrates and by analysis of their rates of aggregation within the defined environment provided by a cone and plate viscometer. Contrary to previous reports, we found that the B16F10 cells (with significant lung-colonizing potential following tail vein injection) were less homotypically adhesive than B16F1 cells (which colonize lungs poorly). The adhesiveness of B16F10 cells approached that of B16F1 cells only under conditions (low shear, low cell number) where cell collisions were thought to be so few that quantitative differences in aggregation rate could not be determined. B16F1 cells also adhered more to lung cells than did B16F10 cells when assessed by aggregation rate. However, analysis of aggregate composition in which one cell type had been fluorescently labelled showed that B16F10 cells actually formed more mixed aggregates with lung cells than did B16F1 cells. There was no significant difference in the adhesiveness of B16F1 or B16F10 cells to liver cells as assessed by aggregation rate. Analysis of aggregate composition under these circumstances, however, showed that B16F10 cells formed fewer mixed aggregates with liver cells than did B16F1 cells. These results are consistent with the possibility that metastatic cells need to display poor homotypic adhesiveness in order to detach from the primary but enhanced heterotypic adhesiveness in order to colonize specific organs.

Entities:  

Mesh:

Year:  1984        PMID: 6537909     DOI: 10.1016/0277-5379(84)90041-5

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  7 in total

1.  Immunomodulatory effects of anti-CD4 antibody in host resistance against infections and tumors in human CD4 transgenic mice.

Authors:  D J Herzyk; E R Gore; R Polsky; K L Nadwodny; C C Maier; S Liu; T K Hart; A G Harmsen; P J Bugelski
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

2.  WT1 silencing by RNAi synergizes with chemotherapeutic agents and induces chemosensitization to doxorubicin and cisplatin in B16F10 murine melanoma cells.

Authors:  Pablo Zapata-Benavides; Edgar Manilla-Muñoz; Diana E Zamora-Avila; Santiago Saavedra-Alonso; Moisés A Franco-Molina; Laura M Trejo-Avila; Guillermo Davalos-Aranda; Cristina Rodríguez-Padilla
Journal:  Oncol Lett       Date:  2012-01-19       Impact factor: 2.967

3.  Malignant melanoma cell lines selected in vitro for increased homotypic adhesion properties have increased experimental metastatic potential.

Authors:  T V Updyke; G L Nicolson
Journal:  Clin Exp Metastasis       Date:  1986 Oct-Dec       Impact factor: 5.150

4.  BPTF Depletion Enhances T-cell-Mediated Antitumor Immunity.

Authors:  Kimberly Mayes; Suehyb G Alkhatib; Kristen Peterson; Aiman Alhazmi; Carolyn Song; Vivian Chan; Tana Blevins; Mark Roberts; Catherine I Dumur; Xiang-Yang Wang; Joseph W Landry
Journal:  Cancer Res       Date:  2016-09-20       Impact factor: 12.701

5.  Substrate adhesiveness and experimental metastatic potential of rat ascites hepatoma AH7974-derived variant sublines.

Authors:  T Kawaguchi; S Igarashi; H Wakabayashi; S Yokoya; K Fukui
Journal:  Clin Exp Metastasis       Date:  1992-07       Impact factor: 5.150

Review 6.  Molecular mechanisms of cell adhesion in normal and transformed cells.

Authors:  R Brackenbury
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

7.  Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice.

Authors:  Kathrin Stirnemann; Jackeline F Romero; Lucia Baldi; Bruno Robert; Valérie Cesson; Gurdyal S Besra; Maurice Zauderer; Florian Wurm; Giampietro Corradin; Jean-Pierre Mach; H Robson Macdonald; Alena Donda
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.